STAAR Surgical Company (STAA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$23.47-0.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · STAA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on growing revenue through market share gains and volume growth, especially in China, Americas, Japan, and EMEA excluding Middle East.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $44.3 million in 2025-Q2 to $93.5 million in 2026-Q2 (+111% Y/Y). China sales more than doubled to $52.3 million in 2026-Q2. Other regions including Americas and EMEA ex-Middle East showed solid growth. Management consistently emphasized revenue growth in key markets and the trajectory is delivering.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We delivered on Revenue Growth with strong demand in China and other key markets.”
“Record first-quarter net sales of $93.5 million, up 119.6% Y/Y, driven by China and Americas growth.”
“Net sales of $57.8 million, up 18.1% Y/Y, with China sales growth offsetting declines elsewhere.”
“Preliminary net sales of $94.7 million, up 6.9% Y/Y, driven by China shipment and growth outside China.”
Drive profitability through gross margin improvement, operating expense discipline, and operating leverage as revenue scales.
Stated as a priority in 4 of last 4 quarters. Gross margin improved from 65.8% in 2025-Q1 to 74.5% in 2026-Q2. Operating income turned positive from a loss of $(29.9) million in 2025-Q2 to $10.1 million in 2026-Q2. Net income improved from $(16.8) million loss to $8.1 million profit over the same period. Management has consistently emphasized profit expansion and operating leverage, and the financials show delivering progress.
“Gross margin at 74.5%, net income $8.1 million, operating income $10.1 million.”
“Gross margin at 73.6%, net income $5.2 million, operating income $8.0 million.”
“Gross margin at 75.7%, net loss $(18.3) million, operating loss $(22.8) million.”
“Adjusted EBITDA improved to positive $20.0 million in 2026-Q2 from loss of $(14.8) million a year ago.”
Accelerate development and launch of new products including EVO+ and next-generation lenses to sustain long-term growth.
Stated as a priority in 3 of last 4 quarters. Management highlights early success of EVO+ launch in China and ongoing preparations for next generation products. While no specific financial metrics are cited, the consistent emphasis on innovation acceleration and product pipeline development indicates a sustained focus.
“Early success with EVO+ launch in China and preparations for next generation products underway.”
“Strong launch of EVO+ ICL in China and advancing product innovation pipeline.”
“Focus on innovation acceleration and strengthening pipeline for mid- and long-term future.”
Reduce excess channel inventory, especially in China, to align with market demand and support sustainable sales growth.
Stated as a priority in 4 of last 4 quarters. Management reports distributor inventory in China normalized to targeted levels by 2026-Q1 and maintained through 2026-Q2, supporting sustainable in-market demand. This aligns with improved sales trends and reduced inventory risk, indicating delivering progress.
“Distributor inventory appears to be within the targeted range to appropriately service the refractive market.”
“Inventories held by distributors are now within targeted ranges with units-on-hand comparable to prior quarter.”
“Distributor inventory reduced to normal levels after prior excess inventory in China.”
“Distributors in China maintained owned inventory at approximately six months, aligned to contractual levels.”
Continue cost reduction efforts, manage operating expenses prudently, and invest selectively to support growth and profitability.
Stated as a priority in 3 of last 4 quarters. Management highlights disciplined expense management with operating expenses reduced 8.2% in 2025-Q4 excluding special items, and investments in ERP and supply chain to improve efficiency. Adjusted EBITDA turned positive in 2026-Q2, indicating delivering progress on cost discipline and capital allocation.
“Investments in ERP and supply chain efficiency while maintaining highest first half adjusted EBITDA results.”
“Achieved targeted operating expense run rate and expect disciplined spending to drive operating leverage.”
“Operating expenses reduced 8.2% excluding merger and restructuring costs.”
Over the trailing year it converted -0.59x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
18 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.